Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 2 · 50%Low 0 · 0%Moderate 1 · 25%High 0 · 0%

Fluvoxamine plus standard care vs placebo + standard care

Serious adverse events during the study period · symptomatic people with COVID‐19

It is very uncertain whether fluvoxamine plus standard care changes serious adverse events (during study period) compared with placebo plus standard care (very low certainty).

1 finding from 1 review

Fluvoxamine for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.56 [0.15, 2.03]
2 studies · 1649 participants
Very low

Azithromycin vs placebo or usual care

Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

1 finding from 1 review

Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 454 participants
Very low

Azithromycin vs placebo or usual care

Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…

Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).

1 finding from 1 review

Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.11 [0.89, 1.4]
4 studies · 794 participants
Moderate

Diclofenac vs placebo

Serious adverse events during the study period · children with acute postoperative pain

The review found no eligible studies for this question.

1 finding from 1 review

Diclofenac for acute postoperative pain in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found